Skip to main navigation
Skip to search
Skip to main content
University of Copenhagen Research Portal Home
Help & FAQ
Dansk
English
Home
Profiles
Research output
Research units
Press/Media
Activities
Prizes
???studenttheses???
Datasets
Search by expertise, name or affiliation
Treatment with GLP-1 Receptor Agonists
Sten Madsbad
,
Jens J. Holst
Department of Clinical Medicine
Department of Clinical Medicine
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Treatment with GLP-1 Receptor Agonists'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Glucagon-like peptide-1 Receptor (GLP-1R)
100%
GLP-1 Receptor Agonist
100%
Gastric Emptying
23%
Hypoglycemia Risk
15%
Adverse Events
15%
Insulin Secretion
15%
Glucagon Secretion
15%
Short-acting
15%
Glucagon-like peptide-1 (GLP-1)
15%
Cardiovascular Endpoints
7%
Long-acting GLP-1
7%
Gastrointestinal Side Effects
7%
Class Differences
7%
Tachyphylaxis
7%
Postprandial Triglycerides
7%
Days of Treatment
7%
Basal Insulin
7%
Popular
7%
Triglyceride Level
7%
Glycemic Control
7%
Blood Pressure
7%
Gastrointestinal Distress
7%
Weight Loss
7%
Type 2 Diabetes Prevention
7%
Obesity Treatment
7%
Delay Effects
7%
Subcutaneous Administration
7%
Nausea
7%
Insulinotropic Effects
7%
Low Risk
7%
Fixed Combination
7%
Neuroprotective Effect
7%
Postprandial Glucose Control
7%
Chronic Treatment
7%
Satiety
7%
Individual Treatment
7%
Type I Diabetes
7%
Head-to-head Comparison
7%
Cardiovascular Effects
7%
Type 1 Diabetes Mellitus (T1DM)
7%
Pulse Rate
7%
Pharmacology, Toxicology and Pharmaceutical Science
Glucagon Like Peptide 1 Receptor Agonist
100%
Glucagon-Like Peptide-1
100%
Hypoglycemia
12%
Gastrointestinal Symptom
12%
Adverse Event
12%
Glucagon
12%
Subcutaneous Injection
6%
Nausea
6%
Tachyphylaxis
6%
Triacylglycerol
6%
Neuroprotective Agent
6%
Non Insulin Dependent Diabetes Mellitus
6%
Insulin Dependent Diabetes Mellitus
6%